Drugs / E7016
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01127178 | Mar 2010 → Feb 2011 | cancer | Eisai Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01605162 | May 2012 → Feb 2014 | melanoma | Eisai Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E7016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01127178 ↗ |
| Known as | GPI-21016 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3527000 ↗ |
| Action | Inhibit | “poly (ADP-Ribose) polymerase inhibitor E7016” NCT01127178 ↗ |
| Modality | Small molecule | — CHEMBL3527000 ↗ |
| Route | Oral | “single oral dose of E7016” NCT01127178 ↗ |